Citations

Clear

922 citation(s) found for "He, Jun".

Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing
Wang, Liwei , Jiang, Min , Nian, Hui , Du, Xianglin L. , Denny, Joshua C. , Xu, Hua , Denny, Joshua C , Wu, Yonghui , Warner, Jeremy L. , Xu, Jun , Chen, Qingxia , Dai, Qi Chang , Yang, Ping , Liu, Hongfang

Mayo Clinic

JCO Clinical Cancer Informatics | May 29, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-9

10.1200/cci.19.00001 | PMID 31141421 Get It

PURPOSEDrug development is becoming increasingly expensive and time consuming. Drug repurposing is one potential solution to accelerate drug discovery. However, limited research exists on the use of electronic health record (EHR) data for drug repurposing, and most published studies have been conducted in a hypothesis-driven manner that requires a predefined hypothesis about drugs and new indications. Whether EHRs can be used to detect drug repurposing signals is not clear. We want to demonstrate the feasibility of mining large, longitudinal EHRs for drug repurposing by detecting candidate noncancer drugs that can potentially be used for the treatment of cancer.PATIENTS AND METHODSBy linking cancer registry data to EHRs, we identified 43,310 patients with cancer treated at Vanderbilt University Medical Center (VUMC) and 98,366 treated at the Mayo Clinic. We assessed the effect of 146 noncancer drugs on cancer survival using VUMC EHR data and sought to replicate significant associations (false discovery rate < .1) using the identical approach with Mayo Clinic EHR data. To evaluate replicated signals further, we reviewed the biomedical literature and clinical trials on cancers for corroborating evidence.RESULTSWe identified 22 drugs from six drug classes (statins, proton pump inhibitors, angiotensin-converting enzyme inhibitors, β-blockers, nonsteroidal anti-inflammatory drugs, and α-1 blockers) associated with improved overall cancer survival (false discovery rate < .1) from VUMC; nine of the 22 drug associations were replicated at the Mayo Clinic. Literature and cancer clinical trial evaluations also showed very strong evidence to support the repurposing signals from EHRs.CONCLUSIONMining of EHRs for drug exposure–mediated survival signals is feasible and identifies potential candidates for antineoplastic repurposing. This study sets up a new model of mining EHRs for drug repurposing signals.
Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.
Gramont, Aimery de , Yin, Jun , Goldberg, Richard M. , Salem, Mohamed E. , Group, Adjuvant Colon Cancer ENd PoinTs (ACCENT), Shi, Qian , Dixon, Jesse G. , Cutsem, Eric Van , Taı̈eb, Julien , Alberts, Steven R. , Wolmark, Norman , Schmoll, Hans‐Joachim , Saltz, Leonard B. , Kerr, Rachel , Lonardi, Sara , Yoshino, Takayuki , Yothers, Greg , Grothey, Axel , André, Thierry , Group, Adjuvant Colon Cancer ENd PoinTs (ACCENT)

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 3502-3502

10.1200/jco.2019.37.15_suppl.3502 Get It

3502 Background: DFS with 3 years median follow-up (3yDFS) was validated as a surrogate for OS with 5 years median follow-up (5yOS) in adjuvant chemotherapy CC trials prior. Recent data showed improved survival after recurrence and OS, over time, in pts who received adjuvant FOLFOX. Hence, re-evaluation of the association between DFS and OS, as well as the optimal follow-up of OS to aid its utility in future adjuvant trials is needed. Methods: Individual patient data from 8 randomized adjuvant studies conducted from 1998-2009 were included; 3 trials tested anti-VEGF or anti-EGFR agents. Trial-level surrogacy examining the correlation of treatment effect estimates (i.e. hazard ratios) of 3yDFS and 5y to 8yOS was evaluated using both linear regression (R2WLS) and Copula bivariate (R2Copula) models. For the R2, a value closer to 1 indicates a stronger correlation. Prespecified criteria for surrogacy required either R2WLS or R2Copula ≥ 0.80 and neither < 0.7, with lower-bound 95% Confidence Interval (CI) > 0.60. The rank correlation coefficient (ρ) quantified the individual-level surrogacy. Results: Total of 18,886 pts were analyzed, with median age 60, 54% male, 83% stage III, 59% > 12 nodes examined. Median follow-up for survival ranged from 5 to 10 years across trials. Trial level correlation between 3yDFS and OS remained strong (R2WLS ≥0.74; R2Copula ≥ 0.89) and increased as the median follow-up of OS extended longer (see table). Analyses limited to stage III pts and/or trials tested biologics showed consistent results. Conclusions: 3yDFS remains a validated surrogate endpoint for 5yOS in adjuvant trials in CC pts per prespecified criteria. The correlation was strengthened with more than 6 years of follow-up for OS. [Table: see text]
Patient-derived organoid (PDO), a new personalized therapy selection tool for prompt clinical decision making in metastatic gastrointestinal (mGI) cancer patients.
Hogenson, Tara L. , Horn, Isaac P. , Almada, Luciana L. , Marks, David I. , Koenig, Amanda, Barrett, Michael T. , Boyum, James H. , Hanson, Temperance J. Scheffler, Yin, Jun , Petersen, Gloria M. , Revzin, Alexander , Billadeau, Daniel D. , Adjei, Alex A. , Fernández-Zapico, Martín E. , Xie, Hao , Tolosa, Ezequiel J. , Mahipal, Amit , Hubbard, Joleen M. , Bekaii‐Saab, Tanios , Wee, Wen

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 3101-3101

10.1200/jco.2019.37.15_suppl.3101 Get It

3101 Background: PDO is a promising translational tool that recapitulates the biology and drug response of donor cancer patient. However, an unmet need is to have PDO drug-screening data available for treatment decision making in clinic. We conducted a pilot study to determine whether PDO testing results will be available at critical treatment decision points in metastatic GI cancer patients. Methods: Metastatic GI cancer patients undergoing core-needle biopsy were eligible. Tumor cells isolated from ≤4 fresh biopsy tissues were grown in a Matrigel-based culture. PDO response to anti-cancer drugs were evaluated; and when available, correlated with donors’ clinical response to the same agent(s). PDO response was defined as IC50 < 0.1 × published Cmax of the drug clinically; stable as IC50 between 0.1 to 10 × Cmax. Radiographic response was per RECIST criteria. Results: We enrolled 27 refractory metastatic GI cancer patients (9 colorectal [CRC], 9 pancreas, and 9 biliary tract). Median lines of therapy were 4, 2, and 2; the success rate of organoid establishment was 89%, 44%, and 55%, respectively. The median time from biopsy to availability of drug-testing data was 64 days (range: 24 to 93 days). The median time from biopsy to next CT re-staging in donors was 64 days. The established PDOs shared histological and genomic features with donor clinical tissue. PDO and clinical responses to the same agent(s) were correlated in 2 CRC donors including (1) BRAFV600E-mutated PDO responded to vemurafenib + panitumumab, as did the donor who had partial response (PDO drug-testing data were available 55 days post-biopsy, 23 days prior to restaging scan); (2) KRAS/FGF-dual amplified PDO had stable disease status to regorafenib, as did the biopsied lesion from the donor (73 days post-biopsy, 5 days post-scan). Conclusions: We showed the feasibility of completing PDO drug sensitivity testing in metastatic GI cancer patients within a short time that could impact clinical decision making, particularly in CRC. PDO drug response showed correlation with clinical response. With further refinement, PDO can be a powerful tool for personalizing cancer therapy in metastatic GI cancer patients.
Adolescent male fertility following reduced‐intensity conditioning regimen for hematopoietic stem cell transplantation in non‐malignant disorders
Zhao, Jun , Beebe, Kristen , Magee, Kyrie, Salzberg, Dana, Stahlecker, Jennifer, Miller, Holly, Adams, Roberta H. , Lipskind, S.T., Walsh, Alexandra , Mirea, Lucia , Ngwube, Alexander

Mayo Clinic

Pediatric Transplantation | May 24, 2019 | Volume: 23 | Issue: 6 | Pages: No page available

10.1111/petr.13496 | PMID 31124253 Get It

AbstractIntroductionThe effects of RIC for HSCT on male fertility remain unknown. We investigated spermatogenesis and gonadal hormonal status among adolescent male patients who received RIC HSCT for non‐malignant diseases.Patients and MethodsPatients with non‐malignant disease who had undergone a RIC HSCT were recruited and evaluated for spermatogenesis via semen analysis and gonadal hormonal function via serum hormone levels. Those who had received prior chemotherapy or radiation were excluded from the study. We reviewed the charts to record demographic factors, conditioning regimen and complications during and after transplant.ResultsFive patients were enrolled. The median age at the time of transplant was 15 years (range, 11‐19 years), and the median time between bone marrow transplant and semen analysis was 5 years (range, 3‐11 years). Median age of patients was 20 years (range, 18‐25 years) at the time of the study. Serum FSH and LH levels were elevated in four patients, and inhibin B levels were low for age in three patients. Semen analysis showed two patients had azoospermia, and the remaining three patients showed severe oligozoospermia. Normal morphology and motility were seen in only one patient.ConclusionThis case series suggests that RIC transplants may be associated with impaired spermatogenesis and sequential follow‐up is necessary given the potential for either permanent impairment or delayed recovery. Further larger studies are needed to confirm these findings.
Faculty Opinions recommendation of Microglia enhance synapse activity to promote local network synchronization.
Wu, Long‐Jun , Eyo, Ukpong B

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | May 23, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.734225279.793560354 Get It

Small Interfering RNA Screening for the Small GTPase Rab Proteins Identifies Rab5B as a Major Regulator of Hepatitis B Virus Production
Inoue, Jun , Ninomiya, Masashi , Umetsu, Teruyuki, Nakamura, Takuya , Kogure, Takayuki , Kakazu, Eiji , Iwata, Tomoaki, Takai, Satoshi, Sano, Akitoshi , Fukuda, Mitsunori , Watashi, Koichi , Isogawa, Masanori , Tanaka, Yasuhito , Shimosegawa, Tooru , McNiven, Mark A. , Masamune, Atsushi

Mayo Clinic

Journal of Virology | May 22, 2019 | Volume: 93 | Issue: 15 | Pages: No page available

10.1128/jvi.00621-19 | PMID 31118260 Get It

HBV infection is a worldwide health problem, but the mechanisms of how HBV utilizes cellular machinery for its life cycle are poorly understood. In particular, it has been unclear how the viral components and virions are transported among the organelles. The HBV budding site has been reported to be the ER or MVB, but it has not been clearly determined. In this study, siRNA-based screening of Rab proteins using HBV-expressing cells showed that Rab5B, one of the Rab5 isoforms, has important roles in late steps of the HBV life cycle. Although Rab5 is known to work on early endosomes, this study showed that Rab5B plays a role in the transport of LHBs between the ER and MVB. Furthermore, it affects the transcription of LHBs. This is the first report on the mechanisms of HBV envelope protein transport among the organelles, and the results provide important insights into the therapeutic control of HBV infection.
SUN-092 Distinct Changes in Gut Microbiota Are Associated with Estradiol-Mediated Protection from Diet-Induced Obesity in Female Mice
Graham, Madeline , Noh, Hye Lim, Suk, Sujin, Friedline, Randall H. , Kim, Jason , Acharya, Kalpana D. , Chen, Jun , Tetel, Marc J.

Mayo Clinic

Journal of the Endocrine Society | May 10, 2019 | Volume: 3 | Issue: Supplement_1 | Pages: No page available

10.1210/js.2019-sun-092 Get It

Faculty Opinions recommendation of Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution.
Bosco, Dale B. , Wu, Long‐Jun

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 10, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.735090979.793558378 Get It

Microglial proliferation and monocyte infiltration contribute to microgliosis following status epilepticus
Feng, Lijie , Murugan, Madhuvika , Bosco, Dale B. , Peng, Jiyun , Ta, Lauren E., Richardson, Jason R. , Shen, Yuxian , Wu, Long‐Jun , Wang, Hai‐Long , Wu, Long-Jun , Liu, Yong , Worrell, Gregory A. , Wang, Hai‐Long

Mayo Clinic

Glia | April 6, 2019 | Volume: 67 | Issue: 8 | Pages: 1434-1448

10.1002/glia.23616 | PMID 31179602 Get It

AbstractMicroglial activation has been recognized as a major contributor to inflammation of the epileptic brain. Seizures are commonly accompanied by remarkable microgliosis and loss of neurons. In this study, we utilize the CX3CR1GFP/+ CCR2RFP/+ genetic mouse model, in which CX3CR1+ resident microglia and CCR2+ monocytes are labeled with GFP and RFP, respectively. Using a combination of time‐lapse two‐photon imaging and whole‐cell patch clamp recording, we determined the distinct morphological, dynamic, and electrophysiological characteristics of infiltrated monocytes and resident microglia, and the evolution of their behavior at different time points following kainic acid‐induced seizures. Seizure activated microglia presented enlarged somas with less ramified processes, whereas, infiltrated monocytes were smaller, highly motile cells that lacked processes. Moreover, resident microglia, but not infiltrated monocytes, proliferate locally in the hippocampus after seizure. Microglial proliferation was dependent on the colony‐stimulating factor 1 receptor (CSF‐1R) pathway. Pharmacological inhibition of CSF‐1R reduced seizure‐induced microglial proliferation, which correlated with attenuation of neuronal death without altering acute seizure behaviors. Taken together, we demonstrated that proliferation of activated resident microglia contributes to neuronal death in the hippocampus via CSF‐1R after status epilepticus, providing potential therapeutic targets for neuroprotection in epilepsy.
MAGI1 as a link between endothelial activation and ER stress drives atherosclerosis
Abe, Jun‐ichi , Ko, Kyung Ae , Kotla, Sivareddy , Paez‐Mayorga, Jesus , Shin, Ik Jae , Imanishi, Masaki , Vu, Hang Thi, Tao, Yunting, Leiva‐Juárez, Miguel M. , Thomas, Tamlyn , Medina, Jan L., Won, Jong Hak, Fujii, Yuka , Giancursio, Carolyn J., McBeath, Elena , Shin, Ji-Hyun, Guzman, Liliana , Abe, Rei , Taunton, Jack , Faubion, William A. , Fujiwara, Keigi , Evans, Scott E. , Le, Nhat‐Tu , Faubion, William, Abe, Rei J , Kotla, Sivareddy , Abe, Jun-Ichi , Wang, Yin , Shin, Ji‐Hyun , Mochizuki, Naoki , Cooke, John P. , Le, Nhat-Tu

Mayo Clinic

JCI Insight | April 3, 2019 | Volume: 4 | Issue: 7 | Pages: No page available

10.1172/jci.insight.125570 | PMID 30944250 Get It

The possible association between the membrane-associated guanylate kinase with inverted domain structure-1 (MAGI1) and inflammation has been suggested, but the molecular mechanisms underlying this link, especially during atherogenesis, remain unclear. In endothelial cells (ECs) exposed to disturbed flow (d-flow), p90 ribosomal S6 kinase (p90RSK) bound to MAGI1, causing MAGI1-S741 phosphorylation and sentrin/SUMO-specific protease 2 T368 phosphorylation-mediated MAGI1-K931 deSUMOylation. MAGI1-S741 phosphorylation upregulated EC activation via activating Rap1. MAGI1-K931 deSUMOylation induced both nuclear translocation of p90RSK-MAGI1 and ATF-6-MAGI1 complexes, which accelerated EC activation and apoptosis, respectively. Microarray screening revealed key roles for MAGI1 in the endoplasmic reticulum (ER) stress response. In this context, MAGI1 associated with activating transcription factor 6 (ATF-6). MAGI1 expression was upregulated in ECs and macrophages found in atherosclerotic-prone regions of mouse aortas as well as in the colonic epithelia and ECs of patients with inflammatory bowel disease. Further, reduced MAGI1 expression in Magi1 –/+ mice inhibited d-flow–induced atherogenesis. In sum, EC activation and ER stress–mediated apoptosis are regulated in concert by two different types of MAGI1 posttranslational modifications, elucidating attractive drug targets for chronic inflammatory disease, particularly atherosclerosis.